BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Releases Q2 Financial Report, Corporate Update
BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, is featured in a recent Aegis Capital Corp. research report. Aegis titled the report “Good Things Coming” and gave BVXV a Buy rating. The research report noted that BiondVax has signed an exclusive worldwide license agreement to develop and commercialize VHH antibodies, called NanoAbs, targeting Interleukin-17 (“IL-17”), specifically for the treatment of psoriasis and psoriatic arthritis. The agreement is with the Max Planck Society and the University Medical Center Gottingen (“UMG”) and is part of an ongoing collaboration BVXV has going with those two entities. According to the report, Max Planck and UMC Gottingen have already generated 11 potential therapeutic candidates. The report noted that the next step for BiondVax is to identify the best two or three of the potential candidates and begin preclinical in vivo proof-of-concept testing and toxicology studies; this would be in preparation for phase 1/2a clinical testing.
“We believe that BiondVax and its collaborators can move quickly, completing the in vivo studies by IH2024 and potentially starting phase 1/2a in 2H2024,” the report stated. “We see the plaque psoriasis market as an excellent opportunity for BiondVax. It’s target, IL-17, is already proven to be effective on even the most severe cases of plaque psoriasis. The NanoAb technology could enable BiondVax to develop an IL-17therapy that is deliverable in a localized manner to psoriatic plaques with the subsequent potential to significantly improve the toxicity profile over systemic IL-17, as well as to provide a novel way to expand the IL-17 market from only severe patients (about 10%–20% of the patient population) to mild and moderate patients (about 80% of the market). If the phase 1 data is positive, which we see as likely, significant interest from big pharma competitors already in the psoriasis market could be expected. . . . We are excited by the direction that BiondVax is taking its unique nanoantibody platform technology. We reiterate our Buy recommendation and $70 price target.”
To view the full report, visit https://ibn.fm/ZkrFF
About BiondVax Pharmaceuticals Ltd.
BiondVax Pharmaceuticals is a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. Since its inception, the company has executed eight clinical trials including a seven-country, 12,400-participant, phase 3 trial of its vaccine candidate; the company has also built a state-of-the-art manufacturing facility for biopharmaceutical products. With highly experienced pharmaceutical industry leadership, BiondVax is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with an innovative nanosized antibody (“NanoAb”) pipeline. For more information about the company, please visit www.BiondVax.com
NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://ibn.fm/BVXV
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information please visit https://www.biomedwire.com
BioMedWire is part of the InvestorBrandNetwork